Metipranolol
CAS: 22664-55-7
Ref. 3D-XAA66455
1mg | Discontinued | ||
2mg | Discontinued | ||
5mg | Discontinued | ||
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued |
Product Information
- (.+-.)-1-(4-Acetoxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-2-propanol
- (.+-.)-Metipranolol
- (RS)-Metipranolol
- 2-Propanol, 1-(4-hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-, 4-acetate
- <span class="text-smallcaps">D</smallcap><smallcap>L</span>-Metipranolol
- Betamet
- Betanol
- Bm 01.004
- DL-Metipranolol
- Disorat
- See more synonyms
- Glauline
- Glausyn
- Methypranol
- Trimepranol
- Turoptin
- Vuab 6453
- Vufb 6453
- [4-[2-Hydroxy-3-(propan-2-ylamino)propoxy]-2,3,6-trimethylphenyl] acetate
- Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2,3,6-trimethyl-, 1-acetate
Metipranolol is a potent inhibitor of tumor growth and metastasis. It is an analog of ghrelin, a hormone that regulates appetite and energy balance. Metipranolol has been shown to induce apoptosis in cancer cells by inhibiting the activity of kinases, which are enzymes involved in cell signaling pathways. This drug has been studied extensively in Chinese hamster ovary (CHO) cells and human urine samples. Metipranolol has demonstrated significant anticancer activity against various types of tumors, including breast, lung, colon, and prostate cancers. Its mechanism of action involves the inhibition of protein kinases that are essential for cancer cell survival and proliferation. Overall, metipranolol represents a promising class of kinase inhibitors for the treatment of cancer.